Pyrazine compounds as inhibitors of FLT3
US11945785B2 · kind B2 · utility
0Cited by
51References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 29, 2022 |
| Grant date | Apr 2, 2024 |
| Priority date | — |
| Expiry date | Dec 29, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/05
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed herein are heterocyclic compounds, for example, according to the following formula and analogs thereof: that inhibit the activity of FLT3. Also described are specific covalent inhibitors of FLT3. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the FLT3 inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of proliferative diseases or conditions, including hematological malignancies and other diseases or conditions dependent on FLT3 activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.